John Radford
机构: Professor of Medical Oncology, University of Manchester
每年引用次数
引用次数
引用: 33,354
H-指数: 92
I10-指数 : 288
出版物: 731
Comparative Quantitation of Lymphoma Gene Signatures in Parallel Formalin Fixed Paraffin Embedded and Frozen Tissue Lymph Nodes
Ebrahim Sakhinia , Jordan Goodchild , Lia Patricia Menasce , Joan Radford
J Clin Exp Pathol 2 ( 128) 2161 -0681.1000
1
2012
Myeloablative therapy for recurrent Hodgkin lymphoma: Good success rates irrespective of previous treatments in the UKLG LY09 trial (ISRCTN97144519)4
M. R. Sydes , J. Radford , M. Cullen , P. W. Johnson
In: ANNALS OF ONCOLOGY. (pp. 91 - 91). OXFORD UNIV PRESS (2008)
2008
Quality of life following cancer treatment: impact of illness perceptions, distress, fatigue, and cognitive failures
O.C. Lindner , A. Wearden , M.G. McCabe , J. Radford
The European health psychologist 17 629
2015
Cognitive impairments and fatigue following lymphoma treatment
J. Radford , C.O. Lindner , A. Wearden
Lunenburg Lymphoma Fatigue Consortium
2015
Gene Expression Profiling of Post-Transplant Lymphoproliferative Disorder using Formalin-Fixed tissue Samples
K Linton , R.J. Byers , S. Usher , J. Adams
In: Winter Pathological Society Meeting; Utrecht. 2013.
2013
Favourable outcome in patients with chemo-refractory HL/ALCL treated with brentuximab vedotin and allogeneic transplant
K. Linton , J. Radford , S. Kulkarni , A. Bloor
11th International Conference on Malignant Lymphoma
2013
A Statistical Framework for Analysing Hypothesised Interactions Between Cells Imaged using Multispectral Microscopy and Multiple Immunohistochemical Markers
V. Clay , K. Linton , R.J Byers , J. Radford
In: Winter Pathological Society Meeting; Utrecht. 2013.
2013
Supplementary Document: The Use of Paclitaxel in the First Line Treatment of Ovarian Cancer
S.M. Beard , J.A. Tidy , J. Radford , R.E. Coleman
Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield
1998
Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after initial chemotherapy is not always required: subsidiary analysis of the UK NCRI RAPID study
P. Hoskin , A. Lister , S. Barrington , J. Radford
British Journal of Haematology 181 24 -24
2018
The use of Cisplatin and Paclitaxel as a first line treatment in ovarian cancer
J. Tidy , R. Coleman , J. Radford , S.M. Beard
Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield
2
1997
Fertility after treatment for cancer: Questions remain over ways of preserving ovarian and testicular tissue
J. Radford , S. Shalet , B. Lieberman
BMJ 319 ( 7215) 935 -936
114
1999
PHASE 1/2A CLINICAL TRIALS OF BI‐1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B‐CELL MALIGNANCIES
I. Karlsson , S. Traub , K. Järås , D. Edwards
Hematological Oncology 37 520 -521
1
2019
CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033)
L.C. Pike , A.A. Kirkwood , P. Patrick , J. Radford
Hematological Oncology 35 37 -38
10
2017
INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
F. Morschhauser , G. Salles , P. McKay , H. Tilly
Hematological Oncology 35 24 -25
47
2017
PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY
P.L. Zinzani , M.A. Fanale , R. Chen , P. Armand
Hematological Oncology 35 136 -137
9
2017
RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033).
J. Trotman , A. Fosså , M. Federico , L. Stevens
Hematological Oncology 35 65 -67
14
2017
BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)
R. Chen , A.L. Gibb , G.P. Collins , R. Popat
Hematological Oncology 35 67 -67
25
2017
Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY)
A. Gibb , S. Pirrie , K. Linton , K. Paterson
Hematological Oncology 35 80 -81
9
2017
APPLICATION OF a GENE EXPRESSION‐BASED MODEL IN COMBINATION WITH FDG‐PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)
C.H. Burton , D. Scott , A.A. Kirkwood , M. Gandhi
Hematological Oncology 35 91 -92
6
2017
TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY
J. Perez De Oteyza , P. Zinzani , S. Iyer , S. Faucette
Hematological Oncology 35 72 -74
3
2017